Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | PPM1B | O75688 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2340545 | 1.00 | MAPT (0.50) | MAPTALDH1A1MEN1KMT2APPM1B | |
| SCHEMBL2339450 | 1.00 | MAPT (0.50) | MAPTALDH1A1MEN1KMT2APPM1B | |
| SCHEMBL2339444 | 1.00 | MAPT (0.50) | MAPTALDH1A1MEN1KMT2APPM1B | |
| SCHEMBL14832682 | 1.00 | MAPT (0.50) | MAPTALDH1A1MEN1KMT2APPM1B | |
| SCHEMBL32678164 | 0.89 | MAPT (0.44) | MAPTALDH1A1MEN1KMT2ACYP3A4 | |
| SCHEMBL2340691 | 0.86 | MAPT (0.47) | MAPTALDH1A1MEN1KMT2APPM1B | |
| SCHEMBL2339415 | 0.86 | MAPT (0.47) | MAPTALDH1A1MEN1KMT2APPM1B | |
| SCHEMBL2337013 | 0.86 | MAPT (0.47) | MAPTALDH1A1MEN1KMT2APPM1B | |
| SCHEMBL2337010 | 0.86 | MAPT (0.47) | MAPTALDH1A1MEN1KMT2APPM1B | |
| SCHEMBL8891623 | 0.84 | MAPT (0.60) | MAPTALDH1A1MEN1KMT2APPM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3226688-B1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME (US) | 2020-07-01 | — | — | EP | disclosed |
| US-10442819-B2 | Tricyclic compounds as inhibitors of mutant IDH enzymes | MERCK SHARP & DOHME CORP. (US) | 2019-10-15 | — | — | US | disclosed |
| EP-2760871-B1 | OXY-CYCLOHEXYL-4H,6H-5-OXA-2,3,10B-TRIAZA-BENZO[E]AZULENES AS V1A ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2018-07-18 | — | — | EP | disclosed |
| US-20170369507-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME CORP. (US) | 2017-12-28 | — | — | US | disclosed |
| EP-3226688-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | Merck Sharp & Dohme Corp. (US) | 2017-10-11 | — | — | EP | disclosed |
| WO-2016089797-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME CORP. (US) | 2016-06-09 | — | — | WO | disclosed |
| US-8828989-B2 | Oxy-cyclohexyl-4H,6H-5-oxa-2,3,10b-triaza-benzo[E]azulenes as V1A antagonists | HOFFMANN-LA ROCHE INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8642590-B2 | Alkylcyclohexylethers of dihydrotetraazabenzoazulenes | HOFFMANN-LA ROCHE INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130079333-A1 | OXY-CYCLOHEXYL-4H,6H-5-OXA-2,3,10B-TRIAZA-BENZO[E]AZULENES AS V1A ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-28 | — | — | US | disclosed |
| EP-2358714-B1 | ALKYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES | HOFFMANN LA ROCHE (CH) | 2012-08-01 | — | — | EP | disclosed |
| EP-2358714-A1 | ALKYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES | F. Hoffmann-La Roche AG (CH) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010057795-A1 | ALKYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-27 | — | — | WO | disclosed |
| US-20100125066-A1 | ALKYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10442819-B2 | Tricyclic compounds as inhibitors of mutant IDH enzymes | IDH3A, IDH2, IDH3B | MAPT 3920/4885ALDH1A1 92/4885MEN1 1305/4885 |
| US-20100125066-A1 | ALKYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES | AVPR1A, AVPR1B, OXTR | MAPT 4699/4885ALDH1A1 298/4885MEN1 1618/4885 |
| US-20130079333-A1 | OXY-CYCLOHEXYL-4H,6H-5-OXA-2,3,10B-TRIAZA-BENZO[E]AZULENES AS V1A ANTAGONISTS | AVPR1A, AVPR1B, ADRA2A | MAPT 3310/4885ALDH1A1 923/4885MEN1 2420/4885 |
| US-20170369507-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | IDH3A, IDH3B, IDH2 | MAPT 3786/4885ALDH1A1 87/4885MEN1 1607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.